TOR complex 2: a signaling pathway of its own.
Identifieur interne : 001481 ( Main/Exploration ); précédent : 001480; suivant : 001482TOR complex 2: a signaling pathway of its own.
Auteurs : Nadine Cybulski [Suisse] ; Michael N. HallSource :
- Trends in biochemical sciences [ 0968-0004 ] ; 2009.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Facteurs de transcription (génétique), Facteurs de transcription (métabolisme), Facteurs de transcription (physiologie), Humains (MeSH), Immunosuppresseurs (pharmacologie), Modèles biologiques (MeSH), Saccharomycetales (métabolisme), Schizosaccharomyces (effets des médicaments et des substances chimiques), Schizosaccharomyces (métabolisme), Sirolimus (pharmacologie), Transactivateurs (génétique), Transactivateurs (métabolisme), Transactivateurs (physiologie), Transduction du signal (effets des médicaments et des substances chimiques), Transduction du signal (génétique).
- MESH :
- effets des médicaments et des substances chimiques : Schizosaccharomyces, Transduction du signal.
- génétique : Facteurs de transcription, Transactivateurs, Transduction du signal.
- métabolisme : Facteurs de transcription, Saccharomycetales, Schizosaccharomyces, Transactivateurs.
- pharmacologie : Immunosuppresseurs, Sirolimus.
- physiologie : Facteurs de transcription, Transactivateurs.
- Animaux, Humains, Modèles biologiques.
English descriptors
- KwdEn :
- Animals (MeSH), Humans (MeSH), Immunosuppressive Agents (pharmacology), Models, Biological (MeSH), Saccharomycetales (metabolism), Schizosaccharomyces (drug effects), Schizosaccharomyces (metabolism), Signal Transduction (drug effects), Signal Transduction (genetics), Sirolimus (pharmacology), Trans-Activators (genetics), Trans-Activators (metabolism), Trans-Activators (physiology), Transcription Factors (genetics), Transcription Factors (metabolism), Transcription Factors (physiology).
- MESH :
- chemical , genetics : Trans-Activators, Transcription Factors.
- chemical , metabolism : Trans-Activators, Transcription Factors.
- chemical , pharmacology : Immunosuppressive Agents, Sirolimus.
- drug effects : Schizosaccharomyces, Signal Transduction.
- genetics : Signal Transduction.
- metabolism : Saccharomycetales, Schizosaccharomyces.
- chemical , physiology : Trans-Activators, Transcription Factors.
- Animals, Humans, Models, Biological.
Abstract
Research on TOR has grown exponentially during the last decade, generating a complex model of the TOR signaling network. Rapamycin treatment provides a simple and straightforward method to inhibit the TOR signaling pathway and to study the influence of TOR on multiple cellular processes. The discovery of two distinct TOR complexes, TORC1 and TORC2, showed that studies using rapamycin targeted only one TOR signaling branch. TORC1 is directly inhibited by rapamycin, whereas TORC2 is not. There is no known TORC2-specific inhibitor, so genetic manipulation is required to study its biological function(s). Many studies in genetically tractable model organisms have expanded our understanding of TORC2 signaling. Here we focus on the TORC2 signaling pathway as revealed by these (mostly recent) studies.
DOI: 10.1016/j.tibs.2009.09.004
PubMed: 19875293
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">TOR complex 2: a signaling pathway of its own.</title><author><name sortKey="Cybulski, Nadine" sort="Cybulski, Nadine" uniqKey="Cybulski N" first="Nadine" last="Cybulski">Nadine Cybulski</name><affiliation wicri:level="1"><nlm:affiliation>Biozentrum, University of Basel, 4056 Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Biozentrum, University of Basel, 4056 Basel</wicri:regionArea><wicri:noRegion>4056 Basel</wicri:noRegion></affiliation></author><author><name sortKey="Hall, Michael N" sort="Hall, Michael N" uniqKey="Hall M" first="Michael N" last="Hall">Michael N. Hall</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19875293</idno><idno type="pmid">19875293</idno><idno type="doi">10.1016/j.tibs.2009.09.004</idno><idno type="wicri:Area/Main/Corpus">001465</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001465</idno><idno type="wicri:Area/Main/Curation">001465</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001465</idno><idno type="wicri:Area/Main/Exploration">001465</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">TOR complex 2: a signaling pathway of its own.</title><author><name sortKey="Cybulski, Nadine" sort="Cybulski, Nadine" uniqKey="Cybulski N" first="Nadine" last="Cybulski">Nadine Cybulski</name><affiliation wicri:level="1"><nlm:affiliation>Biozentrum, University of Basel, 4056 Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Biozentrum, University of Basel, 4056 Basel</wicri:regionArea><wicri:noRegion>4056 Basel</wicri:noRegion></affiliation></author><author><name sortKey="Hall, Michael N" sort="Hall, Michael N" uniqKey="Hall M" first="Michael N" last="Hall">Michael N. Hall</name></author></analytic><series><title level="j">Trends in biochemical sciences</title><idno type="ISSN">0968-0004</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (pharmacology)</term><term>Models, Biological (MeSH)</term><term>Saccharomycetales (metabolism)</term><term>Schizosaccharomyces (drug effects)</term><term>Schizosaccharomyces (metabolism)</term><term>Signal Transduction (drug effects)</term><term>Signal Transduction (genetics)</term><term>Sirolimus (pharmacology)</term><term>Trans-Activators (genetics)</term><term>Trans-Activators (metabolism)</term><term>Trans-Activators (physiology)</term><term>Transcription Factors (genetics)</term><term>Transcription Factors (metabolism)</term><term>Transcription Factors (physiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Facteurs de transcription (génétique)</term><term>Facteurs de transcription (métabolisme)</term><term>Facteurs de transcription (physiologie)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (pharmacologie)</term><term>Modèles biologiques (MeSH)</term><term>Saccharomycetales (métabolisme)</term><term>Schizosaccharomyces (effets des médicaments et des substances chimiques)</term><term>Schizosaccharomyces (métabolisme)</term><term>Sirolimus (pharmacologie)</term><term>Transactivateurs (génétique)</term><term>Transactivateurs (métabolisme)</term><term>Transactivateurs (physiologie)</term><term>Transduction du signal (effets des médicaments et des substances chimiques)</term><term>Transduction du signal (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Trans-Activators</term><term>Transcription Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Trans-Activators</term><term>Transcription Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Immunosuppressive Agents</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Schizosaccharomyces</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Schizosaccharomyces</term><term>Transduction du signal</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Facteurs de transcription</term><term>Transactivateurs</term><term>Transduction du signal</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Saccharomycetales</term><term>Schizosaccharomyces</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteurs de transcription</term><term>Saccharomycetales</term><term>Schizosaccharomyces</term><term>Transactivateurs</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Immunosuppresseurs</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Facteurs de transcription</term><term>Transactivateurs</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Trans-Activators</term><term>Transcription Factors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Models, Biological</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Modèles biologiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Research on TOR has grown exponentially during the last decade, generating a complex model of the TOR signaling network. Rapamycin treatment provides a simple and straightforward method to inhibit the TOR signaling pathway and to study the influence of TOR on multiple cellular processes. The discovery of two distinct TOR complexes, TORC1 and TORC2, showed that studies using rapamycin targeted only one TOR signaling branch. TORC1 is directly inhibited by rapamycin, whereas TORC2 is not. There is no known TORC2-specific inhibitor, so genetic manipulation is required to study its biological function(s). Many studies in genetically tractable model organisms have expanded our understanding of TORC2 signaling. Here we focus on the TORC2 signaling pathway as revealed by these (mostly recent) studies.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19875293</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0968-0004</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Trends in biochemical sciences</Title><ISOAbbreviation>Trends Biochem Sci</ISOAbbreviation></Journal><ArticleTitle>TOR complex 2: a signaling pathway of its own.</ArticleTitle><Pagination><MedlinePgn>620-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tibs.2009.09.004</ELocationID><Abstract><AbstractText>Research on TOR has grown exponentially during the last decade, generating a complex model of the TOR signaling network. Rapamycin treatment provides a simple and straightforward method to inhibit the TOR signaling pathway and to study the influence of TOR on multiple cellular processes. The discovery of two distinct TOR complexes, TORC1 and TORC2, showed that studies using rapamycin targeted only one TOR signaling branch. TORC1 is directly inhibited by rapamycin, whereas TORC2 is not. There is no known TORC2-specific inhibitor, so genetic manipulation is required to study its biological function(s). Many studies in genetically tractable model organisms have expanded our understanding of TORC2 signaling. Here we focus on the TORC2 signaling pathway as revealed by these (mostly recent) studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cybulski</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biozentrum, University of Basel, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Michael N</ForeName><Initials>MN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Biochem Sci</MedlineTA><NlmUniqueID>7610674</NlmUniqueID><ISSNLinking>0968-0004</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493245">CRTC2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C504923">Crtc2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004718" MajorTopicYN="N">Saccharomycetales</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012568" MajorTopicYN="N">Schizosaccharomyces</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>81</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>09</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19875293</ArticleId><ArticleId IdType="pii">S0968-0004(09)00179-0</ArticleId><ArticleId IdType="doi">10.1016/j.tibs.2009.09.004</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Suisse</li></country></list><tree><noCountry><name sortKey="Hall, Michael N" sort="Hall, Michael N" uniqKey="Hall M" first="Michael N" last="Hall">Michael N. Hall</name></noCountry><country name="Suisse"><noRegion><name sortKey="Cybulski, Nadine" sort="Cybulski, Nadine" uniqKey="Cybulski N" first="Nadine" last="Cybulski">Nadine Cybulski</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001481 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001481 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19875293
|texte= TOR complex 2: a signaling pathway of its own.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19875293" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |